Infants less than six months old with Noonan Syndrome, hypertrophic cardiomyopathy and congestive heart failure normally have a poor prognosis, with a one-year survival rate of 34%. In the new study, doctors used Trametinib to try to treat NS in two patients.They observed dramatic improvement of clinical and cardiac status in the patients only three months after treatment.
from EurekAlert! - Breaking News http://bit.ly/2GK7X7P
via IFTTT
Tuesday, April 30, 2019
A promising new treatment for infants with Noonan syndrome
About Admin -
Author Description here.. Nulla sagittis convallis. Curabitur consequat. Quisque metus enim, venenatis fermentum, mollis in, porta et, nibh. Duis vulputate elit in elit. Mauris dictum libero id justo.